← Search & browse all drugs

pheneturide

N03AX13

Forms & Strengths

Oral tablets: 200 mg

Adult Dosing

Initial: 200 to 400 mg daily in divided doses
Maintenance: Titrate gradually up to 600 to 1200 mg daily based on clinical response and tolerability
Maximum recommended daily dose: 1600 mg

Pediatric Dosing

Safety and efficacy in pediatric patients under 6 years are not well established
Children >6 years: Initial 100 to 200 mg daily, titrated gradually based on weight and clinical response

Indications

Management of refractory generalized tonic-clonic seizures
Treatment of complex partial seizures resistant to first-line antiepileptic drugs

Mechanism of Action

Derivatives of phenylacetylurea sharing structural and pharmacological similarities with hydantoins and barbiturates
Stabilizes neuronal membranes and suppresses seizure spread by prolonging the inactive state of voltage-gated sodium channels

Contraindications

Hypersensitivity to pheneturide, other acetylurea derivatives, or hydantoins
Severe hepatic impairment or active liver disease
Severe renal impairment
History of drug-induced bone marrow depression or severe hematologic disorders

Adverse Reactions

Central nervous system: Drowsiness, dizziness, ataxia, fatigue, headache
Gastrointestinal: Nausea, vomiting, anorexia, abdominal pain
Hematologic: Leukopenia, thrombocytopenia, aplastic anemia (rare but severe)
Hepatic: Elevated transaminases, drug-induced hepatitis
Dermatologic: Rash, pruritus, Stevens-Johnson syndrome (rare)

Drug Interactions

CYP enzyme inducers (e.g., carbamazepine, phenobarbital): May decrease pheneturide plasma concentrations
CYP enzyme inhibitors: May increase pheneturide toxicity
Central nervous system depressants (e.g., alcohol, opioids, benzodiazepines): Enhanced sedative and respiratory depressant effects
Coumarin anticoagulants: Anticoagulant effect may be altered due to hepatic enzyme induction or displacement

Curated Content: Needs Vetting Before Put to Clinical Use